360 related articles for article (PubMed ID: 12571218)
1. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.
Henriksen G; Fisher DR; Roeske JC; Bruland ØS; Larsen RH
J Nucl Med; 2003 Feb; 44(2):252-9. PubMed ID: 12571218
[TBL] [Abstract][Full Text] [Related]
2. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Henriksen G; Breistøl K; Bruland ØS; Fodstad Ø; Larsen RH
Cancer Res; 2002 Jun; 62(11):3120-5. PubMed ID: 12036923
[TBL] [Abstract][Full Text] [Related]
3. Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.
Harrison JD; Muirhead CR
Int J Radiat Biol; 2003 Jan; 79(1):1-13. PubMed ID: 12556326
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of 225Ra citrate in mice: retention of daughter radioisotopes in bone.
Kennel SJ; Lankford T; Garland M; Sundberg JP; Mirzadeh S
Nucl Med Biol; 2005 Nov; 32(8):859-67. PubMed ID: 16253811
[TBL] [Abstract][Full Text] [Related]
5. Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology.
Larsen RH; Saxtorph H; Skydsgaard M; Borrebaek J; Jonasdottir TJ; Bruland OS; Klastrup S; Harling R; Ramdahl T
In Vivo; 2006; 20(3):325-31. PubMed ID: 16724665
[TBL] [Abstract][Full Text] [Related]
6. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent.
Jonasdottir TJ; Fisher DR; Borrebaek J; Bruland OS; Larsen RH
Anticancer Res; 2006; 26(4B):2841-8. PubMed ID: 16886603
[TBL] [Abstract][Full Text] [Related]
7. Concerning the health effects of internally deposited radionuclides.
Raabe OG
Health Phys; 2010 Mar; 98(3):515-36. PubMed ID: 20147792
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets.
Dant JT; Richardson RB; Nie LH
Phys Med Biol; 2013 May; 58(10):3301-19. PubMed ID: 23615276
[TBL] [Abstract][Full Text] [Related]
9. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.
Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW
J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212
[TBL] [Abstract][Full Text] [Related]
10. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
13. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer.
Bishayee A; Rao DV; Srivastava SC; Bouchet LG; Bolch WE; Howell RW
J Nucl Med; 2000 Dec; 41(12):2043-50. PubMed ID: 11138691
[TBL] [Abstract][Full Text] [Related]
14. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
[TBL] [Abstract][Full Text] [Related]
15. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides.
Sadremomtaz A; Masoumi M
J Med Imaging Radiat Sci; 2019 Jun; 50(2):272-279. PubMed ID: 31176435
[TBL] [Abstract][Full Text] [Related]
16. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
Pandit-Taskar N; Larson SM; Carrasquillo JA
J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
Chittenden SJ; Hindorf C; Parker CC; Lewington VJ; Pratt BE; Johnson B; Flux GD
J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965
[TBL] [Abstract][Full Text] [Related]
18. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
Henriksen G; Bruland OS; Larsen RH
Anticancer Res; 2004; 24(1):101-5. PubMed ID: 15015582
[TBL] [Abstract][Full Text] [Related]
19. Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male.
Watchman CJ; Jokisch DW; Patton PW; Rajon DA; Sgouros G; Bolch WE
J Nucl Med; 2005 Jul; 46(7):1171-85. PubMed ID: 16000287
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
